EE200200097A - Bensamiididerivaati sisaldav farmatseutiline preparaat - Google Patents
Bensamiididerivaati sisaldav farmatseutiline preparaatInfo
- Publication number
- EE200200097A EE200200097A EEP200200097A EEP200200097A EE200200097A EE 200200097 A EE200200097 A EE 200200097A EE P200200097 A EEP200200097 A EE P200200097A EE P200200097 A EEP200200097 A EE P200200097A EE 200200097 A EE200200097 A EE 200200097A
- Authority
- EE
- Estonia
- Prior art keywords
- pharmaceutical preparation
- preparation containing
- benzamide derivative
- benzamide
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24244499A JP2001081031A (ja) | 1999-08-30 | 1999-08-30 | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| PCT/EP2000/008421 WO2001016106A1 (en) | 1999-08-30 | 2000-08-29 | Benzamide formulation with histone deacetylase inhibitor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200200097A true EE200200097A (et) | 2003-04-15 |
| EE05063B1 EE05063B1 (et) | 2008-08-15 |
Family
ID=17089193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200097A EE05063B1 (et) | 1999-08-30 | 2000-08-29 | Bensamiididerivaati sisaldav farmatseutiline preparaat |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6638530B1 (et) |
| EP (1) | EP1208086B1 (et) |
| JP (2) | JP2001081031A (et) |
| KR (1) | KR100712640B1 (et) |
| CN (1) | CN1147472C (et) |
| AR (1) | AR025434A1 (et) |
| AT (1) | ATE318258T1 (et) |
| AU (1) | AU773617B2 (et) |
| BG (1) | BG65544B1 (et) |
| BR (1) | BR0013648A (et) |
| CA (1) | CA2382886C (et) |
| CZ (1) | CZ301737B6 (et) |
| DE (1) | DE60026144T2 (et) |
| DK (1) | DK1208086T3 (et) |
| EE (1) | EE05063B1 (et) |
| ES (1) | ES2259289T3 (et) |
| HK (1) | HK1046277B (et) |
| HR (1) | HRP20020182B1 (et) |
| HU (1) | HUP0203330A3 (et) |
| IL (2) | IL148357A0 (et) |
| MX (1) | MXPA02002090A (et) |
| NO (1) | NO322532B1 (et) |
| NZ (1) | NZ517520A (et) |
| PL (1) | PL201274B1 (et) |
| PT (1) | PT1208086E (et) |
| RU (1) | RU2260428C2 (et) |
| SI (1) | SI1208086T1 (et) |
| SK (1) | SK287252B6 (et) |
| TW (1) | TWI268778B (et) |
| UA (1) | UA72541C2 (et) |
| WO (1) | WO2001016106A1 (et) |
| ZA (1) | ZA200201424B (et) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US20040116522A1 (en) * | 2001-03-30 | 2004-06-17 | Yutaka Yamagata | Medicinal solutions |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| AU2002327627B2 (en) | 2001-09-14 | 2006-09-14 | Methylgene Inc. | Inhibitors of histone deacetylase |
| AU2006252047B2 (en) * | 2001-09-14 | 2010-02-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| US20040087657A1 (en) | 2001-10-16 | 2004-05-06 | Richon Victoria M. | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
| AU2003211362A1 (en) * | 2002-02-21 | 2003-09-09 | Osaka Industrial Promotion Organization | N-hydroxycarboxamide derivative |
| NZ567758A (en) | 2002-03-04 | 2009-07-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA) |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| WO2003075856A2 (en) | 2002-03-07 | 2003-09-18 | University Of Delaware | Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| DE10233412A1 (de) * | 2002-07-23 | 2004-02-12 | 4Sc Ag | Neue Verbindungen als Histondeacetylase-Inhibitoren |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| GB0226855D0 (en) * | 2002-11-18 | 2002-12-24 | Queen Mary & Westfield College | Histone deacetylase inhibitors |
| US7244751B2 (en) * | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| US7169801B2 (en) | 2003-03-17 | 2007-01-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CN100455564C (zh) * | 2003-09-12 | 2009-01-28 | 深圳微芯生物科技有限责任公司 | 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用 |
| AU2004276337B2 (en) * | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| CN101445469B (zh) * | 2003-09-24 | 2013-02-13 | 梅特希尔基因公司 | 组蛋白脱乙酰基酶抑制剂 |
| US9115090B2 (en) | 2003-12-02 | 2015-08-25 | The Ohio State University Research Foundation | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors |
| WO2005059167A1 (en) * | 2003-12-18 | 2005-06-30 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Method for identifying histone deacetylase inhibitors |
| US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US7642275B2 (en) | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20100087328A1 (en) * | 2005-03-01 | 2010-04-08 | The Regents Of The University Of Michigan | Brm expression and related diagnostics |
| WO2006094068A2 (en) * | 2005-03-01 | 2006-09-08 | The Regents Of The University Of Michigan | Hdac inhibitors that promote brm expression and brm related diagnostics |
| EP1896436A2 (en) | 2005-05-11 | 2008-03-12 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| KR20080032188A (ko) | 2005-07-14 | 2008-04-14 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| US20100152188A1 (en) * | 2005-08-05 | 2010-06-17 | Akella Satya Surya Visweswara Srinivas | Novel Heterocyclic Compounds |
| WO2007117706A2 (en) * | 2006-04-07 | 2007-10-18 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| CA2648804C (en) | 2006-04-07 | 2014-05-27 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| CA2654566A1 (en) * | 2006-06-09 | 2007-12-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| CN101646460A (zh) | 2007-03-28 | 2010-02-10 | 参天制药株式会社 | 含有具有组蛋白脱乙酰化酶抑制作用的化合物作为有效成分的降眼压剂 |
| CA2706750A1 (en) * | 2007-11-27 | 2009-06-04 | Ottawa Health Research Institute | Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
| US20110182888A1 (en) * | 2008-04-08 | 2011-07-28 | Peter Ordentlich | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
| US20090280169A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| EP2285376A4 (en) * | 2008-05-16 | 2011-07-20 | Chipscreen Biosciences Ltd | 6-AMINONICOTINAMIDE DERIVATIVES FORMING POWERFUL AND SELECTIVE HISTONE DEACETYLASE INHIBITORS |
| US8623853B2 (en) | 2008-07-23 | 2014-01-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancers characterized by chromosomal rearrangement of the NUT gene |
| AR075613A1 (es) * | 2009-02-25 | 2011-04-20 | Merrion Res Iii Ltd | Composicion y suministro de drogas de bifosfonato. metodo de tratamiento |
| WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| BR112013017169A2 (pt) | 2011-01-07 | 2016-10-04 | Merrion Res Iii Ltd | composições farmacêuticas de ferro para administração oral |
| CN103172540B (zh) * | 2013-03-18 | 2015-07-01 | 潍坊博创国际生物医药研究院 | 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用 |
| US10184933B2 (en) | 2013-10-01 | 2019-01-22 | The J. David Gladstone Industries | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
| EP3250191B1 (en) | 2015-01-29 | 2024-01-17 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
| CN108349978B (zh) | 2015-07-02 | 2021-07-23 | 安塞塔制药公司 | (S)-4-(8-氨基-3-(1-(丁-2-炔酰基)吡咯烷-2-基)咪唑并[1,5-a]吡嗪-1-基)-N-(吡啶-2-基)苯甲酰胺的固体形式和制剂 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| MX2019000342A (es) * | 2016-07-08 | 2019-09-04 | Ranedis Pharmaceuticals Llc | Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas. |
| WO2018222572A1 (en) * | 2017-06-01 | 2018-12-06 | Warner Babcock Institute For Green Chemistry, Llc | Non-covalent derivatives and methods of treatment |
| US20180353446A1 (en) * | 2017-06-07 | 2018-12-13 | Ranedis Pharmaceuticals, Llc | Compositions and methods of treating and/or preventing cancer |
| US20220211688A1 (en) | 2019-04-25 | 2022-07-07 | Fuji Pharma Co., Ltd. | Pharmaceutical preparation and method for producing the same |
| CN112294810B (zh) * | 2019-07-29 | 2024-03-01 | 深圳微芯生物科技股份有限公司 | 含有西达本胺和表面活性剂的药物组合物 |
| EP4238565A1 (en) | 2020-10-28 | 2023-09-06 | KinoPharma, Inc. | Pharmaceutical composition for preventing or treating viral perivaginal disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ334613A (en) * | 1996-08-12 | 2002-02-01 | Welfide Corp | Pharmaceutical agents comprising Rho kinase inhibitor |
| US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| JP3354090B2 (ja) * | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
| JP4405602B2 (ja) | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
| JP2000256194A (ja) * | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | 核内レセプタ作動薬およびその効果増強剤 |
| JP2001064177A (ja) * | 1999-08-16 | 2001-03-13 | Schering Ag | ベンズアミド誘導体を有効成分とする製剤 |
-
1999
- 1999-08-30 JP JP24244499A patent/JP2001081031A/ja active Pending
-
2000
- 2000-08-29 NZ NZ517520A patent/NZ517520A/en not_active IP Right Cessation
- 2000-08-29 SK SK261-2002A patent/SK287252B6/sk not_active IP Right Cessation
- 2000-08-29 KR KR1020027002163A patent/KR100712640B1/ko not_active IP Right Cessation
- 2000-08-29 ES ES00956496T patent/ES2259289T3/es not_active Expired - Lifetime
- 2000-08-29 TW TW089117485A patent/TWI268778B/zh not_active IP Right Cessation
- 2000-08-29 AT AT00956496T patent/ATE318258T1/de active
- 2000-08-29 US US10/069,582 patent/US6638530B1/en not_active Expired - Fee Related
- 2000-08-29 EP EP00956496A patent/EP1208086B1/en not_active Expired - Lifetime
- 2000-08-29 AU AU68416/00A patent/AU773617B2/en not_active Ceased
- 2000-08-29 UA UA2002032271A patent/UA72541C2/uk unknown
- 2000-08-29 AR ARP000104493A patent/AR025434A1/es unknown
- 2000-08-29 JP JP2001519675A patent/JP2003508386A/ja not_active Withdrawn
- 2000-08-29 CA CA002382886A patent/CA2382886C/en not_active Expired - Fee Related
- 2000-08-29 BR BR0013648-4A patent/BR0013648A/pt not_active Application Discontinuation
- 2000-08-29 RU RU2002107992/15A patent/RU2260428C2/ru active IP Right Revival
- 2000-08-29 DE DE60026144T patent/DE60026144T2/de not_active Expired - Lifetime
- 2000-08-29 CZ CZ20020724A patent/CZ301737B6/cs not_active IP Right Cessation
- 2000-08-29 IL IL14835700A patent/IL148357A0/xx active IP Right Grant
- 2000-08-29 PT PT00956496T patent/PT1208086E/pt unknown
- 2000-08-29 DK DK00956496T patent/DK1208086T3/da active
- 2000-08-29 MX MXPA02002090A patent/MXPA02002090A/es active IP Right Grant
- 2000-08-29 CN CNB008122849A patent/CN1147472C/zh not_active Expired - Fee Related
- 2000-08-29 PL PL353063A patent/PL201274B1/pl not_active IP Right Cessation
- 2000-08-29 SI SI200030851T patent/SI1208086T1/sl unknown
- 2000-08-29 HU HU0203330A patent/HUP0203330A3/hu unknown
- 2000-08-29 EE EEP200200097A patent/EE05063B1/et not_active IP Right Cessation
- 2000-08-29 WO PCT/EP2000/008421 patent/WO2001016106A1/en active IP Right Grant
-
2002
- 2002-02-20 ZA ZA200201424A patent/ZA200201424B/en unknown
- 2002-02-25 IL IL148357A patent/IL148357A/en not_active IP Right Cessation
- 2002-02-26 BG BG106439A patent/BG65544B1/bg unknown
- 2002-02-27 NO NO20020952A patent/NO322532B1/no not_active IP Right Cessation
- 2002-02-27 HR HR20020182A patent/HRP20020182B1/xx not_active IP Right Cessation
- 2002-10-22 HK HK02107642.5A patent/HK1046277B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200097A (et) | Bensamiididerivaati sisaldav farmatseutiline preparaat | |
| FIU20000164U0 (fi) | Uusi farmaseuttinen formulaatio | |
| DK1207868T3 (da) | Farmaceutiske tramadolsalte | |
| PT984773E (pt) | Formulacao farmaceutica a base de omeprazole | |
| ITMI20001450A0 (it) | Nuova composizione farmaceutica | |
| NO20005218L (no) | Farmasöytisk aerosolpreparat | |
| DK1466615T3 (da) | Farmaceutisk præparat | |
| NO20015149D0 (no) | Nytt farmasöytisk preparat | |
| NO20015670D0 (no) | Forbedrede farmasöytiske formuleringer | |
| NO20022606D0 (no) | Farmasöytiske kombinasjoner | |
| NO20014926D0 (no) | Farmasöytiske forbindelser | |
| EE200200073A (et) | Bensamiididerivaati sisaldav farmatseutiline preparaat | |
| NO20015148D0 (no) | Nytt farmasöytisk preparat | |
| EE9900545A (et) | Farmatseutiline kompositsioon | |
| DK1227817T3 (da) | Ciclesonid-holdigt vandigt farmaceutisk præparat | |
| NO20015104D0 (no) | Nytt farmasöytisk preparat | |
| AR025867A1 (es) | Formulacion portasdora farmaceutica | |
| NO20016430L (no) | Farmasöytisk kompleks | |
| NO20015105L (no) | Nytt farmasöytisk preparat | |
| NO20021036L (no) | Farmasöytisk preparat | |
| SE9904819D0 (sv) | A new pharmaceutical composition | |
| SE9800251D0 (sv) | A novel pharmaceutical preparation | |
| DK1060749T3 (da) | Vandigt farmaceutisk præparat indeholdende Tezosentan | |
| DE50008261D1 (de) | Retardierte darreichungsform enthaltend tramadolsaccharinat | |
| SE9804128D0 (sv) | A new pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20110829 |